Guía de práctica clínica para la infección de vías urinarias complicada
Barra lateral del artículo
Contenido principal del artículo
Resumen
La infección de vías urinarias complicada es la infección que ocurre en alguna de las estructuras del tracto urinario, en pacientes con comorbilidad, o con anomalías estructurales o funcionales del tracto urinario. La infección de vías urinarias complicada tiene un alto impacto en morbilidad, mortalidad y en la problemática actual de resistencia a los antimicrobianos, por lo que resulta de importancia generar directrices que permitan orientar el adecuado diagnóstico y tratamiento en este grupo de pacientes, con el objetivo de obtener mejores desenlaces clínicos y propender por un uso racional de antibióticos. La presente guía contiene recomendaciones para el diagnóstico y tratamiento de pacientes adultos con infección de vías urinarias complicada, basadas en la evidencia, realizadas mediante el proceso de adaptación de guías de práctica clínica para el contexto colombiano.
Detalles del artículo
Citas
Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992;15 Suppl 1:S216-27.
Nicolle LE. A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging. 2001;18(4):243-54.
Bonkat G BR, Bruyère F, Cai T, Geerlings SE, Köves B, S. Schubert, F. Wagenlehner. EAU guidelines on Urological Infections. EAU Guidelines. European Association of Urology. 2020;ISBN 978–94–92671–07–3.
Wagenlehner FME, Bjerklund Johansen TE, Cai T, Koves B, Kranz J, Pilatz A, et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol. 2020;17(10):586-600.
Marya D Zilberberg BHN, Kate Sulham, Andrew F Shorr. Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018 Open Forum Infectious Diseases. 2022;9(1).
Marya D. Zilberberg BHN, Kate Sulham & Andrew F. Shorr Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013–2018: a retrospective cohort study. BMC Infect Dis. 2021;21(159).
de Cueto M, Aliaga L, Alós JI, Canut A, Los-Arcos I, Martínez JA, et al. Resumen ejecutivo del diagnóstico y tratamiento de las infecciones del tracto urinario. Guía de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Enfermedades Infecciosas y Microbiologia Clinica. 2017;35(5):314-20.
Antimicrobial resistance: global report on surveillance. World Health Organization. World Health Organization; 2014. Report No.: WHO/HSE/PED/AIP/2014.2.
Ana L Flores-Mireles JNW, Michael Caparon, Scott J Hultgren. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-84.
Colombia. Ministerio de Salud y Protección Socia. Guía Metodológica, Adopción Adaptación de Guías de Práctica Clínica Basadas en Evidencia. Guía metodológica en Internet. Edición 1ª. Bogotá DC. 2017, Disponible en gpc.minsalud.gov.co
Melissa C. Brouwers MEK, George P. Browman,, Jako S. Burgers FC, Gene Feder, Béatrice Fervers,, Ian D. Graham JG, Steven E. Hanna, Peter Littlejohns,, Julie Makarski LZ. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18).
Urinary tract infection (catheter-associated): antimicrobial prescribing NICE guideline. 2018.
Urinary tract infection (lower): antimicrobial prescribing NICE guideline [NG109]. 2018.
Pyelonephritis (acute): antimicrobial prescribing NICE guideline. 2018.
Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. Journal of Clinical Epidemiology. 2017;81:101-10.
Holger J Schunemann RM, Jan Brozek, Nancy Santesso, Pablo Alonso- Coello, Gordon Guyatt, Rob Scholten, Miranda Langendam, Mariska M Leeflang 8, Elie A Akl, Jasvinder A Singh, Joerg Meerpohl, Monica Hultcrantz. GRADE Guidelines: 16. GRADE evidence to decisión frameworks for tests in clinical practice and public health. Journal of Clinical Epidemiology. 2016;76:89-98.
Howard Balshem MH, Holger J Schunemann, Andrew D Oxman, Regina Kunz, Jan Brozek, Gunn E Vist, Yngve Falck-Ytter, Joerg Meerpohl, Susan Norris, Gordon H Guyatt. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology. 2011;64(4):401-6.
Almugbel SK, Alanezi FKB, Alhoshan FM, Alkhalifa RO, Alkhzaim AH, Almohideb MA. Classification and treatment of prostatitis: a review of literature. International Journal Of Community Medicine And Public Health. 2018;5(11).
van Duin D. Diagnostic challenges and opportunities in older adults with infectious diseases. Clin Infect Dis. 2012;54(7):973-8.
Norman DC. Fever in the Elderly. Clinical Infectious Diseases. 2000;31(1).
Rowe TA, Juthani-Mehta M. Urinary tract infection in older adults. Aging Health. 2013;9(5).
Dadzie I, Quansah E, Puopelle Dakorah M, Abiade V, Takyi-Amuah E, Adusei R. The Effectiveness of Dipstick for the Detection of Urinary Tract Infection. Canadian Journal of Infectious Diseases and Medical Microbiology. 2019;2019.
Wilson Michael L, Gaido L. Laboratory Diagnosis of Urinary Tract Infections in Adult Patients. Clinical Infectious Diseases. 2004;38(8).
Pérez Díaz CE, Ojeda JSB. Utilidad del gram de orina en patología quirúrgica urológica: una herramienta olvidada. Urología Colombiana. 2014;23(1).
Lopez J, Cuartas M. Utilidad del citoquímico y la coloración de Gram en muestras de orina en el diagnóstico de las infecciones del tracto urinario en pacientes hospitalizados. Iatreia. 2005;18(4):377-84.
Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. American Journal of Obstetrics and Gynecology. 2018;219(1).
Nicolle LE. Complicated Urinary Tract Infection in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology. 2005;16(6).
Lopez J, Campuzano G. El urocultivo: prueba ineludible para el diagnósticoespecífico de la infección del tracto urinario y el uso racional de los antibióticos. Medicina y laboratorio. 2013;19(5-6):211-42.
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Critical Care Medicine. 2021;49(11).
Leal A, Bocanegra R, Mojica I. Manual de toma de muestras para análisis microbiologico. 2015. p. 1-137.
Nikolaidis P, Dogra VS, Goldfarb S, Gore JL, Harvin HJ, Heilbrun ME, et al. ACR Appropriateness Criteria Acute Pyelonephritis. Journal of the American College of Radiology. 2018;15(11).
Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Therapeutic Advances in Urology: SAGE Publications Inc.; 2019.
Adriana Fernández Lausi AFG, Claudia Rodríguez, Ana Chattas, Javier Farina, Liliana Clara, Yanina Nuccetelli, Flavia Amalfa. Consenso argentino intersociedades de infeccion urinaria 2018-2019 Parte 1 Medicina Buenos Aires. 2020;80(3).
Yamamoto S, Ishikawa K, Hayami H, Nakamura T, Miyairi I, Hoshino T, et al. JAID/JSC Guidelines for Clinical Management of Infectious Disease 2015 Urinary tract infection/male genital infection. Journal of Infection and Chemotherapy. 2017;23(11):733-51.
Caron F, Galperine T, Flateau C, Azria R, Bonacorsi S, Bruyére F, et al. Practice guidelines for the management of adult community-acquired urinary tract infections. Medecine et Maladies Infectieuses. 2018;48(5):327-58.
Kang CI, Kim J, Park DW, Kim BN, Ha US, Lee SJ, et al. Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections. Infection and Chemotherapy. 2018;50(1):67-100.
Díaz-Brochero C, Valderrama-Rios MC, Nocua-Báez LC, Cortés JA. Firstgeneration cephalosporins for the treatment of complicated upper urinary tract infection in adults: A systematic literature review. International Journal of Infectious Diseases. 2022.
Griffith RS. The pharmacology of cephalexin. Postgraduate medical journal. 1983;59 Suppl 5.
Bundtzen RW, Toothaker RD, Nielson OS, Madsen P, Welling PG, Craig WA. Pharmacokinetics of Cefuroxime in Normal and Impaired Renal Function: Comparison of Hig Pressure Liquid Chromatography and Microbiological Assays. 1981.
Olga A. Murillo-Rojas ALL-C, Javier H. Eslava-Schmalbach. Uso de antibióticos en infección de vías urinarias en una unidad de primer nivel de atención en salud, Bogotá, Colombia. Revista salud pública. 2006;4(2):170-81.
Carlos L, Barranco A. Urinary tract infections in the Hospital Universidad del Norte. 2007.
Claudia Patricia Orrego-Marin CPH-M, Cardona-Arias JA. Prevalencia de infección urinaria, uropatógenos y perfil de susceptibilidad antimicrobiana. Acta Med Colomb. 2014;39(4):352-8.
Emelibeth Ambuila González LYRL, Andrea Escobar Bedoya, Mónica Chávez. Prevalencia de uropatógenos Gram negativo aislados de pacientes adultos en la ciudad de Cali. Ciencia & Salud. 2015;4(13):11-7.
Daniel Castrillón Spitia J, Enrique Machado-Alba J, Gómez Idarraga S, Gómez Gutierrez M, Remolina León N, José Ríos Gallego J. Etiología y perfil de resistencia antimicrobiana en pacientes con infección urinaria. Infectio; 2019.
Alviz-Amador A, Gamero-Tafur K, Caraballo-Marimon R, Gamero-Tafur J. Prevalence of urinary tract infection, uropathogens and susceptibility profile in a hospital of cartagena-Colombia in 2016. Revista Facultad de Medicina. 2018;66(3):313-7.
Delgado-Serrano J, Albarracin Ruiz MJ, Rangel-Vera JA, Galeano-Salazar E, Niño-vargas D, Wilches-Cuadros MA, et al. Perfil de resistencia antimicrobiana de aislamientos bacterianos en pacientes con infección urinaria de un centro de referencia en Bucaramanga. MedUNAB. 2020;23(3).
Gupta K HT, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20. doi:10.1093/cid/ciq257).
Pardo SS, Pabón PR, Bermudez D, Sanitas RM. Microbiological susceptibility of community isolated uropathogens in Colombia from 2009-2013 RevMedicaSanitas. 2015;18(2):54-64.
Nocua-Báez LC, Cortés JA, Leal AL, Arias GF, Ovalle-Guerrero MV, Saavedra-Rojas SY, et al. Perfil de sensibilidad antimicrobiana de microorganismos causantes de infecciones urinarias adquiridas en la comunidad en pacientes con diabetes mellitus en Colombia. Biomédica (Bogotá). 2017;37(3):453-60.
Jorge E. Machado-Alba MMM-M. Evaluación de sensibilidad antibiótica en urocultivos de pacientes en primer nivel de atención en salud de Pereira. Revista de Salud Pública. 2012;14(4):710-9.
Martinez P, Garzón D, Mattar S. CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community acquired urinary tract infections in Valledupar, Colombia. Brazilian Journal of Infectious Diseases. 2012;16(5):420-5.
Leal AL, Cortés JA, Arias G, Ovalle MV, Saavedra SY, Buitrago G, et al. Emergencia de fenotipos resistentes a cefalosporinas de tercera generación en Enterobacteriaceae causantes de infección del tracto urinario de inicio comunitario en hospitales de Colombia. Enfermedades Infecciosas y Microbiologia Clinica. 2013;31(5):298-303.
Masters PA, O’Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprimsulfamethoxazole revisited. Arch Intern Med. 2003;163(4):402-10.
FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects [cited 2022 February, 16th]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM513019.pdf.
Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics 2019 [Available from: https://www.ema.europa.eu/en/documents/referral/quinolonefluoroquinolone-article-31-referral-disabling-potentially-permanentside-effects-lead_en.pdf.
Hanberger H, Edlund C, Furebring M, G. Giske C, Melhus A, Nilsson LE, et al. Rational use of aminoglycosides-Review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scandinavian Journal of Infectious Diseases2013. p. 161-75.
Pineda-Posada M, Arias G, Suárez-Obando F, Bastidas A, Ávila-Cortés Y. Factores de riesgo para el desarrollo de infección de vías urinarias por microorganismos productores de betalactamasas de espectro extendido adquiridos en la comunidad, en dos hospitales de Bogotá D.C., Colombia. Infectio. 2017;21(3).
Tumbarello M, Trecarichi EM, Bassetti M, De Rosa FG, Spanu T, Di Meco E, et al. Identifying patients harboring extended-spectrum-Beta-lactamaseproducing Enterobacteriaceae on hospital admission: Derivation and validation of a scoring system. Antimicrobial Agents and Chemotherapy. 2011;55(7):3485-90.
Blanco VM, Maya JJ, Correa A, Perenguez M, Muñoz JS, Motoa G, et al. Prevalencia y factores de riesgo para infecciones del tracto urinario de inicio en la comunidad causadas por Escherichia coli productor de betalactamasas de espectro extendido en Colombia. Enfermedades Infecciosas y Microbiologia Clinica. 2016;34(9):559-65.
Tellez E, Torres F, Saavedra C. Puntaje de Tumbarello en la prediccion de infeccion de vias urinarias por enterobaterias BLEE adquirida en la comunidad- Estudio de prueba diagnostica.Bogota2017
Nino SF, Maldonado N, Biojo J, Ospina RM, Velasquez P, Aguirre H, et al. [Development and validation of a diagnostic model of antimicrobial resistance by extended-spectrum beta-lactamases in communityacquired urinary tract infections. How to adjust the prediction in variable outcome prevalences? The usefulness of contracting predictors with LASSO regression]. Rev Chilena Infectol. 2020;37(6):683-9.
Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum Beta-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy2007. p. 913-20.
Aguilar-Duran S, Horcajada JP, Sorlí L, Montero M, Salvadó M, Grau S, et al. Community-onset healthcare-related urinary tract infections: Comparison with community and hospital-acquired urinary tract infections. Journal of Infection. 2012;64(5):478-83.
Eliakim-Raz N, Babitch T, Shaw E, Addy I, Wiegand I, Vank C, et al. Risk factors for treatment failure and mortality among hospitalized patients with complicated urinary tract infection: A multicenter retrospective cohort study (RESCUING study group). Clinical Infectious Diseases. 2019;68(1):29-36.
Wiggers JB, Sehgal P, Pinto R, MacFadden D, Daneman N. The association of adequate empirical treatment and time to recovery from bacteraemic urinary tract infections: a retrospective cohort study. Clinical Microbiology and Infection. 2019;25(10):1253-8.
Parienti JJ, Lucet JC, Lefort A, Armand-Lefèvre L, Wolff M, Caron F, et al. Empirical therapies among adults hospitalized for community-acquired upper urinary tract infections: A decision-tree analysis of mortality, costs, and resistance. American Journal of Infection Control. 2015;43(9):e53-e9.
Castro E, Cortes J. Revisión sistemática de la respuesta a tratamiento no activo en pacientes con pielonefritis aguda adquirida en la comunidad por microorganismos productores de betalactamasas de espectro extendido. Bogota2021.
David M. Livermore DFJB, John P. Quinn, Yehuda Carmeli, David L. Paterson, Victor L. Yu. Should third generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clinical Microbiology and Infection. 2004;10:84-7.
Peters DM, Winter JB, Droege CA, Ernst NE, Liao S. Comparison of Ceftriaxone and Antipseudomonal Beta-Lactam Antibiotics Utilized for Potential AmpC Beta-Lactamase-Producing Organisms. Hospital Pharmacy. 2021;56(5):560-8.
Kitano Y, Wakatake H, Saito H, Tsutsumi K, Yoshida H, Yoshida M, et al. Clinical outcomes of urinary tract infection caused by extended spectrum beta lactamase producing Enterobacteriaceae: a retrospective observational study comparing patients with and without systemic inflammatory response syndrome. Acute Medicine & Surgery. 2020;7(1).
Cortes J, Sanchez R, Sanchez L, Rosero Y. Efecto del tratamiento inapropiado de pacientes adultos hospitalizados con pielonefritis por manejo empírico con cefuroxima, un estudio de cohorte. Biomédica. 2021;41(3):89-.
Esparza GF, Motoa G, Robledo C, Villegas MV. Aspectos microbiológicos en el diagnóstico de infecciones del tracto urinario. Infectio. 2015;19(4):150-60.
Performance Standards for Antimicrobial Susceptibility Testing, 31st Edition. CLSI M100 ED31:2021.
Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum Beta-lactamases. Journal of Antimicrobial Chemotherapy. 2006;57(4):780-3.
Wells WG WG, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, doubleblind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii67-74. doi: 10.1093/jac/dkh208.
Tomera KM BE, Reyna OG, Jiang Q, Wimmer WM, Woods GL, Gesser RM; Protocol 014 Study Group. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002 Sep;46(9):2895- 900. doi: 10.1128/AAC.46.9.2895-2900.2002.
Bai N SC, Wang J, Cai Y, Liang B, Zhang L, Liu Y, Wang R. Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials. Chin Med J (Engl). 2014;127(6):1118-25. PMID: 24622445.
Lindsey P. Koliscak a, b James W. Johnson,corresponding authora,c James R. Beardsley,a David P. Miller,c John C. Williamson,a,c Vera P. Luther,c and Christopher A. Ohlc. Optimizing Empiric Antibiotic Therapy in Patients with Severe Beta-Lactam Allergy. Antimicrobial Agents and Chemotherapy. 2013;57(12):5918–23.
Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: The revival of old antibiotics. Frontiers in Microbiology: Frontiers Media S.A.; 2014.
Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: A systematic review and metaanalysis of controlled trials. Journal of Antimicrobial Chemotherapy: Oxford University Press; 2015. p. 2456-64.
Al-Dorzi HM, Alsadhan AA, Almozaini AS, A MA, Tamim H, Sadat M, et al. The Performance of Equations That Estimate Glomerular Filtration Rate against Measured Urinary Creatinine Clearance in Critically Ill Patients. Crit Care Res Pract. 2021;2021:5520653.
Pasiechnikov S, Buchok O, Sheremeta R, Banyra O. Empirical Treatment in Patients with Acute Obstructive Pyelonephritis. Infectious Disorders - Drug Targets. 2015;15(3).
Park DW, Peck KR, Chung MH, Lee JS, Park YS, Kim HY, et al. Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in korean adults: A randomized, double-blind, multicenter trial. Journal of Korean Medical Science. 2012;27(5):476-83.
Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A Double-Blind, Randomized Comparison of Levofloxacin 750 mg Once-Daily for Five Days With Ciprofloxacin 400/500 mg Twice-Daily for 10 Days for the Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis. Urology. 2008;71(1):17-22.
Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: A randomised, double-blind, phase 3 trial (ASPECT-cUTI). The Lancet. 2015;385(9981):1949-56.
Vazquez JA, González Patzán LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime-avibactam versus imipenemcilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: Results of a prospective, investigator-blinded, randomized study. Current Medical Research and Opinion. 2012;28(12):1921-31.
Esparza G, Ariza B, Bedoya AM, Bustos I, Castañeda-Ramirez CR, De La Cadena E, et al. Strategies for implementation and reporting of current CLSI breakpoints and phenotypic confirmatory tests for ESBLs and carbapenemases in gram-negative bacilli in Colombian clinical laboratories. Infectio. 2013;17(2):80-9.
Mojica MF, De La Cadena E, Hernandez-Gomez C, Correa A, Appel TM, Pallares CJ, et al. Performance of disk diffusion and broth microdilution for fosfomycin susceptibility testing of multidrug-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2020;21:391-5.
Larson E. Factors associated with variation in estimates of the cost of resistant infections. Med Care. 2010;48(9):767–75.
Lesley Cryer SBS, Melanie Van Amsterdam, Bruce Leff. Costs for ‘hospital at home’ patients were 19 percent lower, with equal or better outcomes compared to similar inpatients. Health Aff (Millwood). 2012;31(6):1237-43.
Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database of Systematic Reviews. 2007.
Puppo P, Germinale F, De Rose AF. Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients. La Clinica terapeutica. 1989;129(2).
Baker PC, Nelson DS, Schunk JE. The Addition of Ceftriaxone to Oral Therapy Does Not Improve Outcome in Febrile Children With Urinary Tract Infections. Archives of Pediatrics & Adolescent Medicine. 2001;155(2).
Millar LK, Wing DA, Paul RH, Grimes DA. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol. 1995;86(4 Pt 1):560-4.
Sanchez M, Collvinent B, Miro O, Horcajada JP, Moreno A, Marco F, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. Emerg Med J. 2002;19(1):19-22.
Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection— 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy. 2013;68(10).
Kyriakidou KG, Rafailidis P, Matthaiou DK, Athanasiou S, Falagas ME. Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: A meta-analysis of randomized controlled trials. Clinical Therapeutics. 2008;30(10).
Darouiche RO, Al Mohajer M, Siddiq DM, Minard CG. Short Versus Long Course of Antibiotics for Catheter-Associated Urinary Tract Infections in Patients With Spinal Cord Injury: A Randomized Controlled Noninferiority Trial. Archives of Physical Medicine and Rehabilitation. 2014;95(2).
Lutters M, Vogt-Ferrier NB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database of Systematic Reviews. 2008.
M Kolár KU, T Látal. Antibiotic selective pressure and development of bacterial resistance. International Journal Of Antimicrobial Agents. 2001;17(5):357-63.
Sharon B Meropol KAC, Zhen Chen, Jonathan A Finkelstein, Sean Hennessy, Ebbing Lautenbach, Richard Platt, Stephanie D Schech, Deborah Shatin, Joshua P Metlay. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf. 2008;17(5):523-32.
Heianza Y, Ma W, Li X, Cao Y, Chan AT, Rimm EB, et al. Duration and Life-Stage of Antibiotic Use and Risks of All-Cause and Cause-Specific Mortality: Prospective Cohort Study. Circ Res. 2020;126(3):364-73.
Alvarez M, Garcia J. Tratamiento de la cistitis desde la farmacia comunitaria. OFFARM Elsevier. 2002:94-9.
Sean Wasserman A, Messina A, Editor del capítulo Gonzalo Bearman B. Guia para el control de infecciones asociadas a la atencion en salud: Paquetes para la prevención de infecciones y prácticas seguras. International Society For Infectious Diseases2018. p. 1-16.
Raz R, Schiller D, Nicolle LE. Chronic indwelling catheter replacement before antimicrobial therapy for symptomatic urinary tract infection. The Journal of urology. 2000;164(4).
M. Lindsay Grayson SC, Suzzane Crowe, William Hope. Kucers’ The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs. 7th edition: CRC Press; 2017.
Cunha BA, Editor. Antibiotic Essentials. Jaypee Brothers Medical Publishers Pvt. Ltd., New Delhi, 2015.